CURx Pharmaceuticals is a specialty pharmaceutical company that licenses, develops and commercializes products that address unmet medical needs. Our focus is on searching for and licensing candidates for development based on sound scientific rationale; strong preclinical and clinical study results; defined regulatory pathway to approval; robust intellectual property protection; and defined market need. Our team cumulatively have over hundred years of experience in the biopharmaceutical industry; have worked for "big pharma” and smaller biotechnology companies; and have developed and marketed several block buster drugs.
Fosfomycin/Tobramycin Inhalation Solution (FTI)
CURx is developing a broad spectrum combination antibiotic consisting of fosfomycin (a phosphonic acid antibiotic with activity against gram-positive and gram-negative bacteria) and tobramycin (an aminoglycoside with potent gram-negative activity) for treatment of patients with Cystic Fibrosis.
Topiramate is a commonly prescribed oral antiepileptic drug . CURx is developing an IV formulation options for patients on maintenance TPM therapy who are temporarily unable to take oral medications..... Read More
Lamotrigine is a commonly prescribed oral antiepileptic drug . CURx would have the only IV/Oral formulation, should our product be approved. CURx is developing an IV formulation options for patients on maintenance LAM therapy who are temporarily unable to take oral medications...Read More